To leverage Immatics' TCR platform with Moderna's mRNA technology across therapeutic modalities including bispecifics, cell therapy and cancer vaccines.
LambdaGen to produce iPSC lines that enhance anti-tumor activity and Plasticell will use its combinatorial screening technology to develop optimal protocols.
To commercialize its cell processing platform, CAR-TXpress, for use in immune cell banking and cell-based contract development and manufacturing services
As companies move their cell and gene therapies through the development process, supporting larger Phase III trials and commercial launches will be a challenge
Ryan Carpentier, Executive Director of Business Development, Cryoport09.23.19